Lyra Therapeutics wants a $58M IPO as biotechs aim to buck volatility

Ear, nose and throat diseases biotech Lyra Therapeutics aims to drive through the coronavirus market volatility and gun for a $58 million IPO.

Lyra Therapeutics wants a $58M IPO as biotechs aim to buck volatility
Ear, nose and throat diseases biotech Lyra Therapeutics aims to drive through the coronavirus market volatility and gun for a $58 million IPO.